The Samsung Life Science Fund is expanding its collaboration in next-generation precision oncology through an investment in U.S. biotech firm Cartography Biosciences.
The Samsung Life Science Fund announced Monday that it has invested in Cartography Biosciences, a U.S. biotech venture.
The Samsung Life Science Fund is a bio-focused fund jointly financed by Samsung C&T (028260), Samsung Biologics (207940) and Samsung Bioepis, and managed by Samsung Venture Investment. The fund focuses on securing innovative technologies from global biotech companies to identify future growth engines.
Cartography Biosciences is a company that possesses an antigen discovery platform technology combining single-cell genetic data with bioinformatics (BI). Based on its proprietary platforms "ATLAS" and "SUMMIT," the company is developing technology that identifies tumor-specific antigens and antigen combinations to enhance the targeting accuracy of antibody therapeutics.
The company's lead pipeline is "CBI-1214," a T cell engager targeting colorectal cancer. The candidate entered Phase 1 clinical trials in early 2026 and is currently enrolling patients.
Through this investment, Samsung plans to strengthen its collaborative foundation with capabilities in gene data-based antigen discovery and new drug development. In particular, the move is expected to accelerate the acquisition of promising technologies in the field of precision medicine-based next-generation anticancer therapies.
"Cartography is a next-generation bio-innovation company with the potential to transform treatment paradigms by combining cancer-specific single-cell genetic data with bioinformatics," said Jung Hyung-nam, Head of the Research Institute and Executive Vice President at Samsung Biologics. "We will continue to support innovative technologies that bring meaningful changes to patients around the world."
